Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$196.82 USD

196.82
2,946,862

-0.14 (-0.07%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Can Novartis (NVS) Spring a Surprise This Earnings Season?

Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.

    Mark Vickery headshot

    Top Stock Reports for Boeing, AbbVie & U.S. Bancorp

    Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).

      Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label

      Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.

        Sweta Killa headshot

        IPO Market Back On Track: ETFs to Tap

        After several lackluster quarters, the U.S. IPO market gained momentum in the second quarter of 2017.

          Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

          Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.

            Novartis' Cosentyx Superior to Stelara in Psoriasis Study

            Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,

              Bristol-Myers Gets FDA Nod for Orencia's Label Expansion

              Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).

                Galapagos-Gilead Begin Phase II Study on Uveitis Candidate

                Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.

                  Bayer Starts Phase III Study for Uterine Fibroids' Candidate

                  Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.

                    Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

                    Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.

                      Arpita Dutt headshot

                      Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod

                      Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.

                        Gilead's (GILD) HCV Drug Application Accepted in the EU

                        Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

                          Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

                          Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

                            AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU

                            AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                              Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

                              Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

                                J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

                                Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

                                  AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?

                                  AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.

                                    Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx

                                    Novartis AG (NVS) announced positive data on arthritis drug Cosentyx from two phase III studies.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug

                                      Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.

                                        AbbVie (ABBV) Announced Positive Phase III RA Candidate Data

                                        AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).

                                          Novartis Biosimilar Pipeline, 2018 Growth Plans on Track

                                          Novartis AG (NVS) announced that the EMA has accepted its applications for biosimilar versions of AbbVie's (ABBV) Humira (adalimumab) and Johnson & Johnson's (JNJ) Remicade (infliximab) for review.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug

                                            Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.

                                              Biogen's Fampyra Conditional Approval Converted to Standard

                                              Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.

                                                The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco

                                                The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco

                                                  AbbVie Down on Humira Patent Loss: Is More Damage in Store?

                                                  AbbVie Inc.'s (ABBV) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. (CHRS),